- Home
- SNDX vs MLNK Comparison
SNDX vs MLNK Comparison
Compare SNDX & MLNK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNDX
- MLNK
- Stock Information
- Founded
- SNDX 2005
- MLNK 1998
- Country
- SNDX United States
- MLNK United States
- Employees
- SNDX N/A
- MLNK N/A
- Industry
- SNDX Biotechnology: Pharmaceutical Preparations
- MLNK Computer Software: Prepackaged Software
- Sector
- SNDX Health Care
- MLNK Technology
- Exchange
- SNDX Nasdaq
- MLNK Nasdaq
- Market Cap
- SNDX 1.1B
- MLNK 1.3B
- IPO Year
- SNDX 2016
- MLNK 2021
- Fundamental
- Price
- SNDX $9.00
- MLNK $17.12
- Analyst Decision
- SNDX Strong Buy
- MLNK Hold
- Analyst Count
- SNDX 10
- MLNK 7
- Target Price
- SNDX $35.80
- MLNK $20.64
- AVG Volume (30 Days)
- SNDX 1.8M
- MLNK 432.7K
- Earning Date
- SNDX 07-31-2025
- MLNK 08-07-2025
- Dividend Yield
- SNDX N/A
- MLNK N/A
- EPS Growth
- SNDX N/A
- MLNK N/A
- EPS
- SNDX N/A
- MLNK N/A
- Revenue
- SNDX $43,722,000.00
- MLNK $319,970,000.00
- Revenue This Year
- SNDX $426.77
- MLNK $6.24
- Revenue Next Year
- SNDX $98.31
- MLNK $5.85
- P/E Ratio
- SNDX N/A
- MLNK N/A
- Revenue Growth
- SNDX N/A
- MLNK 5.15
- 52 Week Low
- SNDX $8.58
- MLNK $15.49
- 52 Week High
- SNDX $25.07
- MLNK $25.33
- Technical
- Relative Strength Index (RSI)
- SNDX 38.70
- MLNK 56.16
- Support Level
- SNDX $8.77
- MLNK $16.09
- Resistance Level
- SNDX $9.50
- MLNK $17.32
- Average True Range (ATR)
- SNDX 0.53
- MLNK 0.57
- MACD
- SNDX -0.04
- MLNK 0.09
- Stochastic Oscillator
- SNDX 14.13
- MLNK 89.17
About SNDX Syndax Pharmaceuticals Inc.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.
About MLNK MeridianLink Inc.
MeridianLink Inc is a cloud-based software solution for financial institutions, including banks, credit unions, mortgage lenders, specialty lending providers, and consumer reporting agencies. It generates maximum revenue from Lending Software Solutions.